QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Monoclonal Antibodies—Classification by Mechanism of Action and Pharmacovigilance

Test your understanding of the concepts covered by Monoclonal Antibodies: Classification by Mechanism of Action and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Where should mechanistic plausibility appear in a signal-assessment process?

As the sole basis for confirming a signal As one component of an integrated assessment alongside clinical, epidemiological, literature, quality and other evidence Only after regulatory action has already been taken Instead of evaluating competing explanations and background risk

Question 2 of 10 Which sequence best represents the article's mechanism-informed reasoning chain?

Clinical outcome → manufacturing change → target identity → antibody origin Molecular characteristics → target engagement → mechanism → physiological consequence → clinical outcome → evidence Adverse event → IgG subclass → route → molecular target Immunogenicity → indication → batch number → receptor expression

Question 3 of 10 Which statement best describes Fc-mediated effector function in the mechanistic framework?

It is always the primary mechanism of every IgG antibody It is a cross-cutting supporting determinant that may contribute to cell depletion or other effects It replaces the need to identify the molecular target It is equivalent to immunogenicity

Question 4 of 10 Which finding would more specifically support an off-target safety hypothesis than an on-target hypothesis?

The expected physiological consequence of inhibiting the intended pathway Evidence of cross-reactivity or unintended interaction with another biological entity A known pharmacodynamic effect at the intended target A clinical response consistent with the authorised mechanism

Question 5 of 10 An antibody binds an antigen on both malignant cells and a normal immune-cell population and recruits immune effectors. Which factor is most important when evaluating potential safety consequences?

Whether the normal cells express the target and may therefore also be depleted Whether the antibody is fully human, regardless of its target distribution Whether the product is administered by injection rather than infusion Whether all Fc-containing antibodies cause the same degree of depletion

Question 6 of 10 Which approach best supports a conclusion that a safety finding may represent a class effect?

Assuming all antibodies with a similar target have identical risks Determining whether the characteristic plausibly explaining the event is shared, expressed and clinically relevant across products Extending a signal solely because products share an IgG subclass Relying only on the product with the largest number of reports

Question 7 of 10 What is the appropriate role of mechanism in a pharmacovigilance safety assessment?

To establish causality whenever an event is biologically plausible To generate and refine safety hypotheses that must be evaluated against empirical evidence To replace individual case assessment and epidemiological evidence To demonstrate that related products share every risk

Question 8 of 10 Why should an antibody that neutralises a soluble ligand not automatically be grouped with an antibody that blocks the ligand's receptor?

Only receptor-binding antibodies can produce clinical effects The two antibodies modify different points in the biological signalling chain Ligand-neutralising antibodies cannot have pathway-related adverse effects Receptor-blocking antibodies are always multispecific

Question 9 of 10 What is the key additional safety consideration for a receptor agonist compared with a receptor-blocking antibody?

The possibility of excessive or prolonged activation of the receptor The certainty that the receptor is expressed only in diseased tissue The absence of any dose or exposure relationship The inability of the antibody to affect normal physiology

Question 10 of 10 Which information should be preserved as case evidence rather than recorded as an established mechanism in an individual case report?

Reported symptoms, laboratory findings and clinical outcome The assessor's unconfirmed hypothesis about target-mediated causality Treatment dates and exposure information Relevant medical history and concomitant medicines

Knowledge Assessment: Monoclonal Antibodies—Classification by Mechanism of Action and Pharmacovigilance

Cookie Settings